(HealthDay News) — Fc gamma receptor 3B (FCGR3B) copy number (CN) loss is associated with increased risk of systemic lupus erythematosus (SLE) and lupus nephritis (LN), according to a meta-analysis published in the International Journal of Rheumatic Diseases.
Jin Yuan, from Huashan Hospital affiliated to Fudan University in Shanghai, and colleagues conducted a systematic literature review and meta-analysis to examine the role of FCGR3B CN in the susceptibility of SLE and LN. Six articles were included in the study, with 5 comparisons of SLE between 2,490 patients and 4,286 controls and 4 comparisons of LN between 689 patients and 1,924 controls.
The researchers found that, compared with the normal genotype, individuals with FCGR3B CN gain did not have increased risk of SLE (odds ratio [OR], 1.07; 95% confidence interval [CI], 0.79 to 1.45; P = 0.65) or LN (OR, 0.83; 95% CI, 0.47 to 1.46; P = 0.52). The risks of SLE and LN were increased for individuals with FCGR3B CN loss (SLE OR, 1.77; 95% CI, 1.51 to 2.06; P < 0.00001; LN OR, 2.02; 95% CI, 1.59 to 2.57; P < 0.00001).
“In conclusion, our meta-analysis confirmed that low FCGR3B CN was related to the increased risk for both SLE and LN,” the authors write.